Сравнительная оценка эффективности и переносимости болезнь-модифицирующих препаратов у больных псориатическим артритом
Диссертация
Псориатический артрит (ПА) является одним из основных воспалительных заболеваний суставов и позвоночника, который представляет собой хронический прогрессирующий системный воспалительный процесс, ассоциированный с псориазом (Пс), локализующийся преимущественно в тканях опорно-двигательного аппарата и приводящий к развитию эрозивного артрита, множественного внутрисуставного остеолиза… Читать ещё >
Список литературы
- Агабабова Э.Р., Бадокин В. В., Эрдес Ш. Ф. и соавт. Разработка и апробация диагностических критериев псориатического артрита. Тер.архив. 1988. — № 12. -С. 117−121.
- Бадокин В.В. Место сульфасалазина в комплексной терапии серонегативных спондилоартритов. Научно-практич. ревматол. 2004. — № 4. — С. 68−72.
- Бадокин В.В. Современная терапия псориатического артрита. Consilium medicum. 2004. — № 3. — С. 181−189.
- Бадокин В.В. Эффективность и переносимость сульфасалазина при ревматических заболеваниях. Научно-практич. ревматол. 2005. — № 4. — С. 47−51.
- Корсакова Ю.Л., Бадокин В. В. Влияние различных доз метотрексата на показатели суставного синдрома у больных псориатическим артритом. Научно-практич. ревматол. 2004. — № 2. — С. 106.
- Насонов Е.Л. Метотрексат: Перспективы применения в ревматологии. М.: Филоматис. 2005.-С. 8−10.
- Пчелинцева А.О., Коротаева Т. В., Корсакова Ю. Л. и др. Эффективность и переносимость лефлуномида при псориатическом артрите. РМЖ. 2006. -№ 25.-С. 1852−1858.
- Aditya K. Gupta, James S., Grober Т. et al. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol 1995- 22:5.
- Aguierre M.A., Velez A., Romero M. et al. Gynecomastia and sexual impotence associated with methotrexate treatment. J Rheumatol 2002- 29:1793−1794.
- Balding J, Kane D, Livingstone W, Mynett-Johnson L, Bresnihan B, Smith O. et al. Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. Arthritis Rheum 2003- 48: 1408−13.
- Barckley L.M., Bullaboy C.A., Leichtman L. et.al. Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of mother. Arthritis Rheum 1997- 40: 971−3.
- Belzuneque J., Intxausti J., De Dios J. et al. Absence of pulmonary fibroses in patients with psoriatic arthritis treated with weekly low dose methotrexate. Clin Exp Rheumatol 2001- 19:7227−7230.
- Black R.L., O’Brien W.M., van Scott E.G. et al. Methotrexate therapy in psoriatic arthritis: double blind study on 21 patients. JAMA 1964- 189: 743−747.
- Borogna C., Endo L., Anaya L.M. et al. Methotrexate concentration in synovial membrane and trabecular and trabecular and cortical bone in rheumatoid arthritis patients. Arthritis Rheum 1994- 37- 12: 1770−1773.
- Boumpas D., Tassiulas I. Psoriatic arthritis. In: Primer on the Rheumatic disease: an official publication of the Arthritis Foundation, Klippel J.H. ed. Atlanta, arthritis Foundation 1998- 175−179.
- Boey O., Van Hooland S., Woestenburg A. Methotrexate should not be used for patients with end-stage kidney disease. Acta Clin Belg 2006- 61: 166−169.
- Breedveldt F., Dayer J. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000- 59: 841−849.
- Brockbank J., Schentag C., Rosen C. et al. Psoriatic arthritis (PsA) is common among patients with psoriasis and family medicine clinical attendees. Arthritis Rheum 2001- 44: Suppl.:S94.
- Canete J. et al. Ectopyc lymphoid neogenesis in psoriatic arthritis. Ann Rheum Dis 2007- 66: 720−726.
- Cantarini L., Ninnazi I., Biasi D. Sulfasalazine-induced immune thrombocytopenia. Postgrad Med J 2007- 83:1.
- Cannon G., Jackson C., Samuelson C. et al. Chlorambucil therapy in rheumatoid arthritis: clinical experience in 28 patients and literature review. Semin Arthritis Rheum 1985- 15: 106−118.
- Cantini F., Niccoli L., Nannini C. et al. Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. Rheumatology 2008- 9: 1−5.
- Carette S., Calin A., McCafferty J. et al. A double-blind placebo-controlled study of auronafin in patients with psoriatic arthritis. Arthritis Rheum 1989- 32: 158−165.
- Carniero J., Sato E. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1999- 26: 1275−1279.
- Chandran V., Schentag С., Gladman D. Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum 2007- 57(8): 1560−1563.
- Charlotte Egsmose, Troels Mork Hansen, Lis Smedegaard Andersen, et al. Limited effect of sulphasalazine treatment in reactive arthritis. A randomized double blind placebo controlled trial. Ann Rheum Dis 1997- 56: 32−36.
- Chen J., Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2005- 18(2): CD004800.
- Clegg D., Reda D., Mejias E. at al. Comparasion of sulfasalazine and placebo for the treatment of psoriatic arthritis and cutaneous psoriasis. Arthritis Rheum 1996- 39: 2013−2020.
- Clegg D., Reda D., Weisman M. et al. Comparasion of sulphasalazine and placebo in the treatment of reactive arthritis (Reiterys syndrome). A Department of Veterans Affairs Cooperative study. Arthritis Rheum 1996- 39: 2013−2020.
- Clegg L., Reda D., Abdelatif M. Comparasion of sulphasalazine for the treatment and placebo of axial and peripheral articular manifestations of the seronegative spondyloarthropaties. Arthritis Rheum 1999- 42: 2325−2329.
- Combe В., Kinowski J.M., Bologna C. et al. Effect of renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. Arthritis Rheum 1997- 40: suppl S94.
- Costello P., Winchester R.J., Curran S.A. et al. Psoriatic arthritis joint fluids are characterized by CD8 and CD4 cell clonal expansions that appear antigen driven. J Immunol 2001- 166:2878−2886.
- Сгаппеу A., Mckendry R., Wells G.A. et al. The effect of low dose methotrexate on bone dencity. J Reumatol 2001- 28: 2395−2399.
- Cronstein B. The mechanism of action of methotrexate. Ann Rheum Dis 1997- 23: 739−755.
- Cuchacovich M., Soto L. Leflunomide decreases joint erosions and induces reparative changes in a patient with psoriatic arthritis. Ann Rheum Dis 2002- 61: 942−943.
- Cuellar M., Espinoza L. Methotrexate use in psoriasis and psoriatic arthritis. Ann Rheum Dis. Clin North Am 1997- 23: 797−809.
- Daniel О., Clegg D., Reda D. et al. Comparison of sulfasalasine and placebo in the treatment of psoriatic arthritis. Arthritis Rheum 1996- 39: 2013−2020.
- Dougados M., Linden S., Leirisalo-Repo M. et al. Sulphasalazine in the treatment spondyloarthropathy. Arthritis Rheum 1995- 38: 618−627.
- Dougados M., Maetzel A., Mijiyawa M. et al. Evaluation of sulphasalazine in the treatment of spondyloarthropathies. Ann Rheum Dis 1992- 51:955−958.
- Eiichi Tanaka, Atsuo Taniguchini, Wako Urano. et al. Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J Rheumatol 2002- 29:12.
- Elkayam O., Yaron I., Shirazi I. et al. Serum levels of IL-10, IL-6, IL-lra, and sIL-1R in patients with psoriatic arthritis. Rheumatol Int 2000- 19: 101−105.
- Furst D.E. Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. Br J Rheumatol 1995- 34, suppl.: 20−25.
- Fearon U., Veal D. Pathogenesis of psoriatic arthritis. Clin Exp Dermatol 2001- .26:333−337.
- Feltelius N., Gudmundson S., Wennersten L. et al. Enumeration of IgA producting cells by the enzyme linked immunospot technique to evaluate sulfasalazine effects in inflammatory arthritides. Ann Rheum Dis 1991- 50: 369−371.
- French A., Koren G., Motherisk T. Effect of methotrexate on male fertility. Can Fam Physician 2003−49:577−578.
- Fuchs H. Use of sulphasalazine in rheumatic diseases. Bull Rheum Dis 1997- 46: 3.
- Furst D. Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. Br J Rheumatol 1995- 34, suppl.: 20−25.
- Getov I., Dimitrova L., Petrova V. Low dose treatment with methotrexate — adverse drug reactions survey. Boll .Chim Farm 2000- 139: 153−158.
- Gladman D. Effectiveness of psoriatic arthritis therapies. Semin Arthritis Rheum 2003−33:29−37.
- Gladman D., С Antoni, Mease P. et al. Psoriatic arthritis: epidemiology, clinical features, corse, and outcome. Ann Reum Dis 2005- 64, Supp II: 14−17.
- Gladman D., Brockbank J. Psoriatic arthritis. Expert. Opin. Investig. Drugs. 2000- 9: 1511−1522.
- Gladman D., Heilliwell P., Mease P. et al. Assessment of patients with psoriatic arthritis. Arthritis Rheum 2004- 50: 24−35.
- Gladman D., Tung H., Schentag C. et al. Remission in psoriatic arthritis. Rheumatology 2001- 28: 1045−1048.
- Goe V, Berthelot J., Joly P. et al. Leflunomide induced subaqute cutaneous lupus erythematosus. J Rheumatol 2005- 44: 823−824.
- Gomes-Vaquero C., Rodrigues-Moreno J., Ros S. et al. Termination of disease-modifying drugs in psoriatic arthritis: study of 109 courses of treatment. Br J Rheumatol 1996- 35: 564−567.
- Goupille Combe P., Kunts J. et al. Sulphasalazine in psoriatic arthritis a randomized, multicentre, placebo-controlled study. Br J Rheumatol 1996- 35: 664−668.
- Cranney AB., McKendry RJ., Kanigsberg ND. et al. The effect of low dose methotrexate on bone density. J Rheumatol 2001−28:2395−2399.
- Haibel H., Rudwaleit M., Braun J. et al. Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis 2005- 64:124−126.
- Hartving P., Simonsson В., Oberg G. et al. Inter and antrain individual differens in oral chlorambucil pharmacokinetic. Eur J Clin Pharmacol 1998- 35: 551−554.
- Hoehler Т., Marker-Hermann E. Psoriatic arthritis: clinical aspects, genetic and the role of T cells. Curr Opin Rheumatol 2001- 13: 273−279.
- Husted J., Gladman D., Long J. et al. Modifed version of the Health Assesment Questionare (HAQ) for psoriatic arthritis. Clin Exp Rheumatol 1995- 13: 439−443.
- Jones G., Crotty M., Brooks P. Interventions for treating psoriatic arthritis. Cochrane Database Syst Rev 2000- 2: CD000212.
- Kaltwasser J., Nash P., Gladman D. et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004- 50: 1939−1950.
- Kamarashev J., Lor P., Forster A. et al. Generalised pustular psoriasis induced by cyclosporine a withdrawal responding to the tumor necrosis factor alfa ingibitor etanercept. Clin Exp Dermatol 2002−205:213−216.
- Kane D., Roth J., Frosch M. et al. Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis. Arthritis Rheum 2003- 48: 1676−1685.
- Kane D., Stafford L., Bresnihan B. et al. A prospective? Clinical and radiological study of early psoriatic arthritis: an early synovitas clinic experience. Rheumatology 2003- 42:1460−1468.
- Kauppi M. et al. Increased risk of leukaemia in patients with juvenile chronic arthritis treated with chlorambucil. Acta Paediatr 1996- 85: 248−250.
- Kers O., Murry C., Tidman M. Subacute cutaneous lupus erythematosus associated with leflunomide. Clin Exp Dermatol 2004- 29: 319−320.
- Kitas G., Farr M., Waterhouse L. et al. Influence of acetylator on sulfasalazine efficacy and toxicity in patients with rheumatoid arthritis. Scand J Rheumatol 1992- 21:220−225.
- Kremer J., Galivan J. Streckfuss A. et al. Methotrexate analysis in blood and liver of rheumatoid arthritis patients: association with hepatic folate deficiency and formation of polyglutamate. Arthritis Rheum 1986- 29: 832−833.
- Lacaille D., Stein H.B., Raboud J. et al. Long-term therapy of psoriatic arthritis: intramuscular gold or methotrexate? J Rheumatol 1997- 27: 1922−1927.
- Laversuch C., Collins D., Charles P. et al. Sulphasalazine-induced autoimmune abnormalities in patients with rheumatic diseases. Br J Rheumatol 1995- 34: 435−439.
- Lawson C., Fraser A., Veale D. et al. Cyclosporin treatment in psoriatic arthritis: a course of severe leg pain. Ann Rheum Dis 2003- 62: 489.
- Lee I., Gladman D., Schentag C. et al. The long-term use of azathioprine in patients with psoriatic arthritis. J Clin Rheumatol 2001- 7: 160−165.
- Lindqvist Ulla R., Alenius Gerd-Marie, Husmark T. et al. The swedish early psoriatic arthritis register 2-year followup: a comparison with early rheumatoid arthritis. J Rheumatol 2008- 35: 668−673.
- Marguerie L, Flipo R, Grasdel B. et al. Use of disease-modifying antirheumatic drugs in patients with psoriatic arthritis. Joint Bone Spine 2002- 69: 275−281.
- McKendry R., Kraag G., Seigel S. Therapeutic value of colchicines in the treatment of patients with psoriatic arthritis. Ann Rheum Dis 1993- 52: 826−828.
- Minaur N., Jefferis C., Bhalla A. et al. Methotrexate in the treatment of rheumatoid arthritis. In vitro effects on cells of the osteoblast lineage. Rheumatology (Oxford). 2002- 41: 735−740.
- Mladenovic V., Dommljian Z., Rosman B. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 1995- 38: 1595−1603.
- Mpofu S., Smith P., Moots R. et al. Cytostatic therapy for AA amyloidosis complicating psoriatic spondyloarthropathy. J Rheumatol 2003- 42: 362−366.
- Nash P. Clegg D. Psoriatic arthritis therapy: NSAIDS and traditional DMARDs. Ann Rheum Dis 2005- 64: 74−77.
- Palit J., Hill J., Capell N. et al. A multicentral double-blind comparison auronafin, intramuscular gold thiomalat and placebo in patients with psoriatic arthritis. Br J Rheumatol 1990- 29: 280−283.
- Partsch G, Steiner G, Leeb B. et al. Hignly increased levels of tumor necrosis-alpha and others proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997- 24: 518−523.
- Peter J., Nash P., Gladman D. et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis. Arthritis Rheum 2004- 50: 1939−1950.
- Quiero R., Belzunequi J., Gonzales C. et al. Clinically asymptomatic axial disease in psoriatic spondyloarthropathy. A retrospective study. Clin Rheumatol 2002- 21: 1030.
- Quiero R., Sarasqueta C., Belzunequi J. Psoriatic spondyloarthropathy: a comparative study between HLA-B27 positive and HLA-B27 negative disease. Semin Arthritis Rheum 2002- 31:413−418.
- Raffayova H., Rovensky J., Malis F. Treatment with cyclosporine in patients with psoriatic arthritis: results of clinical assessment. Int J Clin Pharmacol Res 2000- 20: 1−11.
- Rahman P., Gladman D., Cook R. et al. Radiological assessment in psoriatic arthritis. Br J Rheumatol 1998- 37: 760−765.
- Ravindran V., Scott D L., Choy E H. A systematic review and meta-analysis of efficacy and toxicity of disease modyfying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis 2008- 67: 855−859.
- Richard J., Peter L. et al. The antiinflammatory drug sulfasalazine ingibits tumor necrosis factor a expression in macrophages by inducing apoptosis. Arthritis Rheum 2000- 43: 1941−1950.
- Rooney R.W., Furst D.E., Koehnke R., Burmeister L. Aspirin is not associated with more toxicity than other NSAID in patients with RA treated with methotrexate. J Rheumatol 1993- 20: 1297−302.
- Salaffi F., Manganelli P., Carotti M. et al. Methotrexate induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature. Clin Rheumatol 2001- 19: 727−730.
- Salvarani C., Macchioni P., Olivieri I. et al. A comparasion of cyclosporine, sulphasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 2001−28:2274−2282.
- Sampaio-Barros P., Costallat L., Bertolo M. et al. Methotrexate in the treatment of ankylosing spondylitis. Scan J Rheumatol 2000- 29: 160−2.
- Sazzi-Puttini P., Cazzova M., Panni B. et al. Long-term safety and efficacy of low-dose cyclosporine A in severe psoriatic arthritis. Rheumatol Int 2002- 21: 234−238.
- Schiff M., Whelton A. Renal toxicity associated with disease-modifying anturheumatic drags used for the treatment of rheumatoid arthritis. Semin Arthritis Rheum 2000- 30: 196−208.
- Schwab U., Moller J., Zurborn K. et al. Increased incidence of methotrexate associated severe cytopenia in elderly patients. Arthritis Rheum 1997- 40, suppl: 54.
- Schwartz P., Barnett S., Atillasoy E. et al. Methotrexate induces differentiation of human keratinocytes. Proc. Natl. A cad. Sci. USA 1992- 89: 594−598.
- Segal R., Yoron M., Tarlackovski B. Methotrexate: mechanism of action in rheumatoid arthritis. Semin Arthritis Rheum 1990- 20: 190−199.
- Solganick J., Tan M., Lebwohl M. A guide to systemic psoriasis treatment: methotrexate. Psoriasis forum 2000- 6: 4−5.
- Spadaro A., Riccieri V., Sili-Scavalli A. et al. Comparison of cyclosporine A and methotrexate in the treatment of psoriatic arthritis: A one-year prospective study. Clin. Exp. Rheumatol 1995- 13: 589−593.
- Steinberg A.D. Chlorambucili in the treatment of in patients immune-mediated rheumatic-disease. Arthritis Rheum 1993- 36: 325−328.
- Steinsson K., Jonsdottir I., Valdimarsson H. Cyclosporin A in psoriatic arthritis: an open study. Ann Rheum Dis 1990- 49: 603−606.
- Taylor W., Gladman D., Helliwell P. Classification criteria for psoriatic arthritis development of new criteriafrom a large international study. Arthritis Rheum 2006- 54:2665−2673.
- Taylor W., Korendowych.E., Nash P. et al. Drug use the toxicity in psoriatic disease: focus on methotrexate. J Rheumatol 2008- 35: 1454−1457.
- Uehara R., Suzuki Y., Ichikawa Y. Methotrexate osteoblastic differentiation is possible mechanism of methotrexate osteopathy. J Rheumatol 2001- 28: 251−256.
- Ulubas В., Sahin G., Ozer C. et al. Bronchiolitis obliterans organizing pneumonia associated with sulfasalazine in a patient with rheumatoid arthritis. J Clin Rheumatol 2004- 23:249−251.
- Van Jaarsveld H., Jahangier Z., Jacobs J. et al. Toxicity of anti-rheumatic drugs in a randomized clinical trial of early rheumatoid arthritis. Rheumatol (Oxford) 2000- 39: 36−42.
- Veale D J, Ritchlin C, Fitzgerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005- 64, Suppl II: 26−29.
- Willkens R., Williams H., Ward J. et al. Randomized double blind, placebo controlled trial of low dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984- 27:376−381.
- Wollina U., Stander K., Barta U. Toxicity of methotrexate treatment in psoriasis and psoriatic arthritis Short and long-term toxicity in 104 patients. Clin Rheumatol 2001- 20: 406−410.
- Woltsche M., Woltsche-Kahr I., Roeger G. et al. Sulfasalazine-indused extrinsic alveolitis in a patient wih psoriatic arthritis. Eur J Med Res 2001- 20: 495−497.
- Yusted J.A., Gladman D.D., Long J.A. et al. Modified version of the Health assessment Questionnare (HAQ) for psoriatic arthritis. Clin Exp Rheumatol 1995- 13:439−443.
- Zachariae H. Prevalens of joint disease in patient with psoriasis: implications for therapy. Am J Clin Dermatol 2003−4:441−447.
- Zonneveld I.M., Bakker W.K., Dijkstra P.F. et al. Methotrexate osteopathy in long-term, lose-dose methotrexate treatment for psoriasis and rheumatoid arthiritis. Arch Dermatol 1996- 132: 184−7.